FDA Approves Lazcluze With Rybrevant for Non-Small Cell Lung Cancer

The FDA has approved lazertinib (Lazcluze, Janssen Biotech) in combination with amivantamab-vmjw (Rybrevant, Janssen Biotech) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.

Efficacy was evaluated in MARIPOSA (ClinicalTrials.gov. Identifier: NCT04487080), a multicenter, randomized, active-controlled trial of